Aflibercept
As of the edition of 20 October 2026, Aflibercept is a protein: marketed, first approved in 2011 (US); acts on PGF and VEGFA; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Protein
- Brand name
- Eylea
- First approved
- 18 November 2011 (US)
- Approvals on record
- 27 in 5 regions
- Holder of the most recent approval
- Amgen; 6 holders in all
- Registered trials
- 362, 44 stopped early
- Disease areas
- Eye; Cancer; Heart and blood vessels; Hormones; Digestive system; Nervous system
US protection
US protection ends in 2030.
The orphan exclusivity ends in 2030 (it covers one use only). The application that gives this date is held by Regeneron.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Aflibercept.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 85 | 56 | 15 | 5 |
| Phase 1 | 37 | 28 | 3 | 3 |
| Phase 2 | 101 | 63 | 8 | 22 |
| Phase 3 | 66 | 50 | 8 | 6 |
| Phase 4 | 73 | 45 | 4 | 8 |
| All trials | 362 |